This article was originally published in The Gray Sheet
Human cellular or tissue products manufacturers regulated under 21 CFR 1270 must register and list products by May unless President Bush decides to include the reg in his regulatory review plan, FDA says in Feb. 13 Q&As on the agency's Tissue Action Plan (21 CFR 1271), which is comprised of three regulations. On Jan. 18, the agency signed off on the registration rule (1"The Gray Sheet" Jan. 22, p. 10); FDA will rescind 21 CFR 1270 once it finalizes two remaining rules covering donor suitability and good tissue practice. Manufacturers of products not regulated under 21 CFR 1270; device manufacturers must register and list with revised Form 3356 by Jan. 21, 2003
You may also be interested in...
Manufacturers of combination devices incorporating human cells or tissues will have until Jan. 19, 2003 to register with FDA, according to a final rule released by the agency Jan. 18.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.